share_log

ST康美(600518.SH):公司股票申请撤销其他风险警示

Kangmei Pharmaceutical (600518.SH): The company's stocks apply for the revocation of other risk warnings.

Gelonghui Finance ·  Jun 26 07:01

On June 26th, Gelonhui reported that the corresponding situation of the 'other risk warning' triggered by Kangmei Pharmaceutical Co., Ltd. for the negative opinion of internal control issued within the 2020 annual audit report has been eliminated. The financial loan contract dispute case between Bohai International Trust Co., Ltd. and Kangmei (Bozhou) Huatuo International Traditional Chinese Medicine City Co., Ltd., Bozhou New World Trading Co., Ltd. has been finally judged and entered the execution procedure. The company has taken measures to safeguard the company's legitimate rights and interests, and the company's profitability continues to increase. The company will apply to the Shanghai Stock Exchange for the revocation of the 'other risk warning' in accordance with relevant regulations. The final application for revocation shall be subject to the audit opinion of the Shanghai Stock Exchange. At that time, the company will fulfill its information disclosure obligations in a timely manner. On June 26, 2024, the company held the third interim meeting of the ninth board of directors in 2024 and approved the 'proposal to apply for the revocation of the company's stock other risk warning', and agreed that the company should apply to the Shanghai Stock Exchange for the revocation of the 'other risk warning'.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment